Cargando…

Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria

Hutchinson-Gilford progeria syndrome (HGPS) is caused by the accumulation of a farnesylated form of prelamin A (progerin). Previously, we showed that blocking protein farnesylation with a farnesyltransferase inhibitor (FTI) ameliorates the disease phenotypes in mouse model of HGPS (Lmna(HG/+)). Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shao H., Chang, Sandy Y., Andres, Douglas A., Spielmann, H. Peter, Young, Stephen G., Fong, Loren G.
Formato:	Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803242/ https://www.ncbi.nlm.nih.gov/pubmed/19965595 http://dx.doi.org/10.1194/jlr.M002808

Ejemplares similares

Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
por: Arnold, Rouven, et al.
Publicado: (2021)

Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts
por: Gabriel, Diana, et al.
Publicado: (2017)

Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells
por: Mehta, Ishita S, et al.
Publicado: (2011)

Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors
por: Holland, Andrew J., et al.
Publicado: (2015)

Defective Lamin A-Rb Signaling in Hutchinson-Gilford Progeria Syndrome and Reversal by Farnesyltransferase Inhibition
por: Marji, Jackleen, et al.
Publicado: (2010)

Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome fibroblasts
por: Bikkul, Mehmet U., et al.
Publicado: (2018)

Activating the synthesis of progerin, the mutant prelamin A in Hutchinson–Gilford progeria syndrome, with antisense oligonucleotides
por: Fong, Loren G., et al.
Publicado: (2009)

Nuclear membrane ruptures underlie the vascular pathology in a mouse model of Hutchinson-Gilford progeria syndrome
por: Kim, Paul H., et al.
Publicado: (2021)

New targets for therapy in breast cancer: Farnesyltransferase inhibitors
por: Head, Julia, et al.
Publicado: (2004)

Effect of farnesyltransferase inhibitor on the function of mitochondria of Plasmodium falciparum
por: Ha, Young Ran, et al.
Publicado: (2012)

Bacteria Are New Targets for Inhibitors of Human Farnesyltransferase
por: Weber, Lea, et al.
Publicado: (2021)

Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum
por: Ha, Young Ran, et al.
Publicado: (2015)

Bioactivity of Farnesyltransferase Inhibitors Against Entamoeba histolytica and Schistosoma mansoni
por: Probst, Alexandra, et al.
Publicado: (2019)

An overview on natural farnesyltransferase inhibitors for efficient cancer therapy
por: Dai, Xiaohan, et al.
Publicado: (2020)

Effect of farnesyltransferase inhibitors on SARS-CoV-2
por: Weber, Lea, et al.
Publicado: (2023)

New targeted therapies in myelodysplastic syndrome: the role of farnesyltransferase and proteasome inhibitors
por: Gonçalves, A Cristina, et al.
Publicado: (2010)

Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor
por: DeGeorge, Katharine C, et al.
Publicado: (2008)

Phenothiazine- and Carbazole-Cyanochalcones as Dual Inhibitors of Tubulin Polymerization and Human Farnesyltransferase
por: Zubaș, Andreea, et al.
Publicado: (2023)

In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida
por: Qiao, Jianjun, et al.
Publicado: (2013)

Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors
por: Nigam, Aradhya, et al.
Publicado: (2023)

Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments
por: Ha, Nguyen Thi, et al.
Publicado: (2020)

Progeria
Publicado: (1935)

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
por: Gajewski, Thomas F, et al.
Publicado: (2012)

Virtual Lead Identification of Farnesyltransferase Inhibitors Based on Ligand and Structure-Based Pharmacophore Techniques
por: Al-Balas, Qosay A., et al.
Publicado: (2013)

Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice
por: Cuddy, Leah K., et al.
Publicado: (2022)

The secretome atlas of two mouse models of progeria
por: Quintana‐Torres, Diego, et al.
Publicado: (2023)

Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice
por: Tanaka, Tomokazu, et al.
Publicado: (2018)

Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
por: Dozier, Jonathan K., et al.
Publicado: (2014)

Analyzing the postulated inhibitory effect of Manumycin A on farnesyltransferase
por: Hagemann, Anna, et al.
Publicado: (2022)

A Farnesyltransferase Acts to Inhibit Ectopic Neurite Formation in C. elegans
por: Carr, David, et al.
Publicado: (2016)

MALDI-MS Analysis of Peptide Libraries Expands the Scope of Substrates for Farnesyltransferase
por: Schey, Garrett L., et al.
Publicado: (2021)

Living with Progeria
por: Stamsnijder, Marjet
Publicado: (2010)

In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells
por: Giudice, V, et al.
Publicado: (2016)

2D-QSAR study of some 2,5-diaminobenzophenone farnesyltransferase inhibitors by different chemometric methods
por: Ghanbarzadeh, Saeed, et al.
Publicado: (2015)

Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson–Gilford Progeria Syndrome
por: Kang, So-mi, et al.
Publicado: (2023)

Redox theory in progeria
por: Villa-Bellosta, Ricardo
Publicado: (2020)

New treatments for progeria
por: Villa-Bellosta, Ricardo
Publicado: (2019)

The pursuit of therapy for progeria
por: Saxena, Saurabh, et al.
Publicado: (2021)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

Hutchinson–Gilford Progeria Syndrome: Clinical and Molecular Characterization
por: Pachajoa, Harry, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rpsh1q5ugs3go50d2g87k5dblq